|Articles|June 13, 2023
Transduction for AAV with Sean Hart
Author(s)Chris Spivey
Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured.
Advertisement
Chris Spivey, editorial director, speaks with Sean Hart, CEO and SCO of LumaCyte, on percent transduction for AAV measured. The full discussion can and more can be viewed
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
2
Q&A: Strategies for Supply Chain Resilience and Next-Generation Process Optimization
3
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
4
BioPharma By the Numbers: Bioprocess Hiring Creating Capacity Constraints
5
